In Brief: Genetic Therapy, Inc.
Executive Summary
Genetic Therapy, Inc.: Licenses exclusive worldwide rights to a patent application for a gene therapy approach using HS-tk gene to induce susceptibility of brain tumors to ganciclovir therapy from Bristol-Myers Squibb. GTI has an HS-tk/ganciclovir therapy in Phase I/II trials in collaboration with Sandoz. The patent application was filed by Massachusetts General Hospital and is "the earliest application known to GTI" for the approach, GTI said...